痛泻要方治疗腹泻型肠易激综合征的系统评价与Meta分析
结果显示S-TXYF在整体症状改善方面优于西药和安慰剂(GRADE中等证据),在粪便性状、排便频率、腹痛方面优于安慰剂,在生活质量与焦虑缓解方面优于西药;但纳入试验设计总体不足,尚不能得出确证性结论。
要点
- S-TXYF对IBS-D整体症状改善优于西药和安慰剂,GRADE证据为中等。
- S-TXYF在粪便性状、排便频率和腹痛改善方面显著优于安慰剂。
- S-TXYF在生活质量和焦虑缓解方面优于西药,安全性报告未见严重不良事件。
核心结论
- 当前结果提示S-TXYF可能对IBS-D有治疗潜力且使用似乎安全,但纳入试验设计总体不足,尚不能得出明确确证结论。
主要发现
- 在整体症状改善方面,S-TXYF优于西药和安慰剂(GRADE中等证据)。
- 在粪便性状、排便频率和腹痛改善方面,S-TXYF显著优于安慰剂。
- S-TXYF在改善生活质量和缓解焦虑方面优于西药。
- 6项试验报告不良事件:5项报告两组均发生非严重不良事件;1项报告S-TXYF组3例不良事件(便秘、肝酶升高、恶心),安慰剂组3例不良事件(腹胀、恶心)。
临床怎么用
- S-TXYF可作为IBS-D整体症状改善的潜在治疗选择,但需结合试验设计局限性谨慎解读证据。
- 使用S-TXYF时应关注便秘、肝酶升高、恶心等不良事件,并监测安全性。
局限性
- 纳入试验总体设计不足,无法得出确证性结论。
- 需更多严格设计的试验来确证S-TXYF的获益与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) significantly decreases the quality of life of patients and their families, and affects patients' mental health. No specific western medications are available. Ancient classical Chinese medical texts have recognized Tongxie Yaofang (TXYF) as a therapy for diarrhea which is widely used in clinical practice. Standard TXYF prescription (S-TXYF) is composed of four herbal medicines: Atractylodes macrocephala Koidz. [Asteraceae; Rhizoma Atractylodis Macrocephalae.], Paeonia lactiflora Pall. [Ranunculaceae; Paeoniae Radix Alba], Citrus × aurantium L. [Rutaceae; Citri Reticulatae Pericarpium] and Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. [Umbelliferae; Saposhnikoviae Radix]. This review aimed to evaluate the therapeutic effects and safety of S-TXYF for IBS-D. Methods: Eight English and Chinese electronic databases were searched from their inception to 25 December 2021 for randomized controlled trials (RCTs) comparing S-TXYF with placebo, western medications or no treatment for IBS-D. The primary outcome was the global improvement of IBS-D symptoms. Data were analyzed using Cochrane's Revman 5.4 software. Evidence certainty was assessed using the online GRADEpro tool for the primary outcome. Results: Eleven RCTs involving 985 adults with IBS-D were included. For global improvement of symptoms, S-TXYF was superior to western medication and placebo (moderate evidence by GRADE). Regarding the improvement of stool consistency, stool frequency and abdominal pain, S-TXYF was significantly effective than placebo. In addition, S-TXYF was superior to western medication on improving the quality of life and relieving anxiety. Six trials reported adverse events: five of them reported (non-serious) adverse events occurred in both groups, and one trial reported that 3 cases with adverse events (constipation, elevation in liver-enzyme, nausea) occurred in S-TXYF group and 3 cases with adverse events (abdominal distension, nausea) occurred in placebo group. Conclusion: Although current results showed that S-TXYF may have potential to treat IBS-D and its use appears to be safe, no a clear and confirmed conclusion can be drawn from our review as the overall inadequate design of the included trials reviewed. So more rigorous trials are warranted to establish confirmed evidence on its benefits and safety.
引用
- Liang SB, Cao HJ, Kong LY, et al. Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials. Front Pharmacol. 2022. PMID: 36091782. doi:10.3389/fphar.2022.904657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。